Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

P-glycoprotein expression in bladder cancer

J Park1, N Shinohara, M Liebert

  • 1Department of Pathology, University of Michigan, Ann Arbor.

The Journal of Urology
|January 1, 1994
PubMed
Summary

P-glycoprotein, a cause of multi-drug resistance in cancer, is present in most bladder tumors even without prior chemotherapy. Combining doxorubicin with verapamil showed no improved efficacy in a small trial.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.

International journal of obesity (2005)·2013
Same author

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.

Diabetes, obesity & metabolism·2013
Same author

The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.

Diabetes, obesity & metabolism·2013
Same author

Transferring preterm infants from incubators to open cots at 1600 g: a multicentre randomised controlled trial.

Archives of disease in childhood. Fetal and neonatal edition·2011
Same author

New treatment approaches for superficial and invasive bladder cancer.

Urologic oncology·2011
Same author

Markers of bladder cancer State of the art.

Urologic oncology·2011

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Multi-drug resistance (MDR) is a major challenge in cancer chemotherapy.
  • P-glycoprotein (P-gp) is a key mediator of MDR, acting as an efflux pump.
  • Understanding P-gp expression in bladder cancer is crucial for treatment strategies.

Purpose of the Study:

  • To evaluate P-glycoprotein expression in bladder cancer specimens.
  • To assess the correlation between P-gp expression and response to doxorubicin.
  • To investigate the efficacy of intravesical doxorubicin combined with verapamil to overcome P-gp-mediated resistance.

Main Methods:

  • P-glycoprotein expression analysis in 29 cystectomy specimens and 9 bladder biopsies.
  • Evaluation of patient response to intravesical doxorubicin.

Related Experiment Videos

  • Pilot trial of intravesical doxorubicin and verapamil in 5 patients.

    • Main Results:

    • P-glycoprotein was expressed in 75% of cystectomy specimens.
    • No correlation found between baseline P-gp expression and doxorubicin response.
    • The doxorubicin-verapamil combination was well-tolerated but did not demonstrate increased efficacy.

    Conclusions:

    • P-glycoprotein can be expressed in bladder cancer cells prior to chemotherapy exposure.
    • The clinical significance of P-gp-mediated MDR in bladder cancer treatment failure requires further investigation.
    • Novel strategies may be needed to effectively overcome P-gp-mediated resistance in bladder cancer.